Funding activity in the sector was strong, with Encoded Therapeutics raising $275 million for gene therapy, Moonwalk Biosciences securing $70 million for obesity research, and Caspian Therapeutics launching with $50 million. However, Boston Scientific warned it will miss 2026 targets following an August cyberattack, and Tyra Biosciences saw its stock drop 38% after Phase 2 data missed benchmarks. Additionally, the FDA appointed permanent leadership for its drug and vaccine centers, while Beeline Medicines moved its oral lupus drug into Phase 3.
01Company specific
Moonwalk Therapeutics Secures $70M to Advance Obesity siRNA Therapy
Eli Lilly co-investing in fat-targeted siRNA signals that weight-loss incumbents are actively hedging against muscle-loss limitations inherent to appetite-suppressing incretins.
Moonwalk Biosciences closed a $70 million Series B funding round to advance its lead obesity candidate into human clinical testing by the end of 2027. Wave and YK Bioventures co-led the financing, which included participation from pharmaceutical giant Eli Lilly alongside existing backers ARCH Venture Partners, Khosla Ventures, and Future Ventures. The will fund investigational new drug-enabling studies for MW101, an adipose-targeted small interfering RNA therapeutic designed to act directly on fat tissue rather than through appetite suppression. By silencing genes involved in metabolic dysfunction within fat cells, the biotechnology company aims to avoid limitations of current incretin drugs such as lean muscle loss and high discontinuation rates. The financing also supports the expansion of additional siRNA pipelines addressing mechanisms like lipolysis, adipogenesis, and thermogenesis, backed by tissue-targeting chemistry licensed from Suzhou Siran Biotechnology. Eli Lilly takes a strategic position in the syndicate as it monitors next-generation weight-loss technologies alongside its own blockbuster incretin . Moonwalk previously raised a $57 million Series A in 2024 to build its discovery platform, pivoting its focus from target identification to clinical translation.
Encoded Closes $275 Million Series F to Advance Dravet Syndrome Drug
Demonstrating clinical efficacy before raising mega-rounds allows monogenic gene therapy developers to command late-stage capital even after severe early-stage cost restructuring.
Encoded Therapeutics closed a $275 million Series F financing round to fund a pivotal study of its Dravet syndrome drug and expand internal manufacturing capabilities. GV and an undisclosed healthcare fund co-led the round, with participation from ARCH Venture Partners, Janus Henderson Investors, RTW Investments, and SoftBank Vision Fund. The will advance ETX101, an AAV9-based gene therapy for SCN1A-positive Dravet syndrome, alongside an investigational new drug application submission for ETX301 planned for 2027. The financing follows a workforce reduction of 29% in February 2025 that preserved capital for earlier clinical development. That trial subsequently produced a 78% reduction in seizures.
Kura Oncology Launches $50 Million Lilly-Backed Diabetes Spinout
Splitting metabolic assets into a Lilly-backed vehicle protects oncology margins while keeping exposure to a menin inhibitor's potential transition into chronic disease treatment.
Kura is spinning out its diabetes pipeline into a new biotech called Caspian Therapeutics with $50 million in initial financing. The funding round was led by BVF Partners and included Eli Lilly, the T1D Fund, Invus, Montanova, and members of Kura's leadership team. Caspian will use the to advance its lead menin inhibitor, KO-7246, through early-phase in diabetes and cardiometabolic diseases. Kura originally observed that targeting menin, a protein involved in cell division, controlled blood sugar levels in animal studies alongside its known effects against leukemia. Kura will retain about 50 percent ownership of the new spinout. Kura CEO Troy Wilson will serve as executive chair of Caspian's board, while Robert Spencer will lead the company as head. The spinout allows Kura to focus on rolling out its leukemia drug Komzifti while external capital funds the diabetes research.
FDA Permanently Appoints Acting Heads for Drug and Vaccine Centers
Permanent leadership at the drug and biologics oversight divisions provides regulatory predictability for biotech pipelines while establishing a dedicated office to accelerate tech-driven trial reviews.
The Trump administration named Michael Davis and Karim Mikhail as permanent directors of the Center for Drug Evaluation and Research and the Center for Evaluation and Research on September 8, 2026. Both officials had been running the divisions on an interim basis since May following a period of turnover that included the resignation of former commissioner Marty Makary. The Health and Human Services Department also appointed Jared Seehafer as the agency's first deputy commissioner for technology and , alongside Bret Koplow as director of the Center for Tobacco Products. Analysts noted the appointments should bring stability and a return to more flexible regulatory decision-making while the industry awaits the Senate confirmation of Heidi Overton as permanent commissioner.
Boston Scientific Unlikely to Meet 2026 Targets Following Cyberattack
When physical sterilization and distribution backlogs force analysts to write off a medical device maker's entire fiscal year, operational downtime becomes a multi-quarter valuation reset.
Boston Scientific will miss its full-year 2026 sales and targets following a cyberattack that paralyzed its global manufacturing and shipping operations. An unauthorized intrusion on August 25 knocked out key business applications and forced the medical device maker to halt customer order processing. While major distribution centers and sterilization facilities have resumed normal operations, the resulting has clouded the company's financial visibility. Stifel analyst Rick Wise told clients that investors now view 2026 as a lost year and are shifting their focus to 2027 prospects. Boston Scientific plans to issue revised when it reports third-quarter earnings on October 28.
Tyra Biosciences Advances Bladder Cancer Drug to Pivotal Trial Despite Stock Drop
Accepting lower efficacy than rival pan-FGFR inhibitors allows Tyra to position dabogratinib on a superior safety profile, trading top-line response for zero treatment-related discontinuations.
Tyra Biosciences will advance its bladder cancer drug dabogratinib to a registrational study next year after reporting initial Phase 2 data that missed Wall Street targets. The trial tests the oral, FGFR3-selective inhibitor in low-grade intermediate-risk non-muscle-invasive bladder cancer across 50-mg and 60-mg arms. Investors sent Tyra stock down 38% to $19.30 at market open Wednesday from a Tuesday close of $26.73, after the pooled complete response rate fell short of the 70% set by analysts. H.C. Wainwright and Guggenheim analysts established that threshold using Johnson & Johnson's THOR-2 study of Balversa, a pan-FGFR inhibitor that achieved a 72% complete response rate but drew criticism for off-target toxicity. Tyra reported grade 3 or worse treatment-emergent adverse events of 9% in the 50-mg arm and 14% in the 60-mg cohort, with no dose reductions or treatment-related discontinuations in the 60-mg group. The company identified the 60-mg dose for its registrational adjuvant development strategy and plans to enroll a 70-mg cohort to assess the drug in an ablative setting.
Tyra Biosciences Share Price ($)
Tyra shares fell 38% following the Phase 2 data release.
Beeline Medicines Advances Lupus Drug to Phase 3 Following Promising Data
Advancing an acquired TLR inhibitor into final-stage clinical trials validates spin-out development models that rely on venture funding to scale big-pharma assets without early licensing partners.
Beeline Medicines is advancing its oral lupus drug afimetoran into development after the candidate hit its primary endpoint in a phase 2 trial. The trial tested the small-molecule inhibitor of Toll-like receptors 7 and 8 against a placebo across 48 weeks of daily treatment in patients with systemic lupus erythematosus. All three doses of afimetoran produced significantly higher SRI-4 response rates than the placebo cohort, with a p-value of less than 0.001. Beeline acquired afimetoran alongside four other from Bristol Myers Squibb as part of a that was backed by a $300 million launch in April and a $126 million series A extension in June. While competitors including Germany's Merck KGaA have advanced rival treatments into phase 3, Beeline executives intend to retain solo control over the asset's path to regulatory approval.
Strong funding for gene therapy and obesity research contrasts with severe operational fallout at Boston Scientific and clinical disappointments at Tyra. The main question is whether fresh capital and regulatory stability can offset manufacturing vulnerabilities and mixed trial outcomes across biotech.
This, every morning.
SuMarket writes Healthcare and Pharmaceutical Sector every morning, along with every other section of the market and the companies and topics you follow. Free to read.